Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study focuses on people with a type of cancer called Multiple Myeloma, as well as other conditions that are similar. The researchers want to use the patient's own immune cells to target proteins that are found in these tumor cells. They are using a new experimental therapy called Tumor Associated Antigen (TAA)-specific cytotoxic T lymphocytes (CTLs). These cells target proteins that are specific to the cancer cells and not found in normal cells. The researchers are targeting five specific proteins in this study. The purpose of the study is to find a safe dose of the TAA-specific CTLs and to see if this therapy can help people with the conditions described above. The therapy is currently not approved by the Food and Drug Administration.
This study focuses on people with a type of cancer called Multiple Myeloma, as well as other conditions that are similar. The researchers want to use the patient's own immune cells to target proteins that are found in these tumor cells. They are using a new experimental therapy called Tumor Associated Antigen (TAA)-specific cytotoxic T lymphocytes (CTLs). These cells target proteins that are specific to the cancer cells and not found in normal cells. The researchers are targeting five specific proteins in this study. The purpose of the study is to find a safe dose of the TAA-specific CTLs and to see if this therapy can help people with the conditions described above. The therapy is currently not approved by the Food and Drug Administration.
*Third Opinion AI Generated Synopsis
Trial Summary
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune cells known as T lymphocytes.This research study uses special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs), a new experimental therapy. The proteins that investigators are targeting in this study are called tumor associated antigens (TAAs). These are cell proteins that are specific to the cancer cell.They either do not show or show up in low quantities on normal human cells. In this study the investigators are targeting five common TAAs called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. On a different protocol, patients have been treated and so far this treatment has shown to be safe. Investigators now want to try this treatment in patients with multiple myeloma or if the investigators can arrest the progression of the patient's condition condition (described above) to multiple myeloma. These TAA-specific CTLs are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the largest safe dose of TAA-specific CTLs, to learn what the side effects are, and to see whether this therapy might help patients with multiple myeloma monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM) .
This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells seen in patients with multiple myeloma. The investigators would like to target proteins that are expressed by these cells using the patient's own immune cells known as T lymphocytes.This research study uses special immune system cells called tumor associated antigen (TAA)-specific cytotoxic T lymphocytes (CTLs), a new experimental therapy. The proteins that investigators are targeting in this study are called tumor associated antigens (TAAs). These are cell proteins that are specific to the cancer cell.They either do not show or show up in low quantities on normal human cells. In this study the investigators are targeting five common TAAs called NY-ESO-1, MAGEA4, PRAME, Survivin and SSX. On a different protocol, patients have been treated and so far this treatment has shown to be safe. Investigators now want to try this treatment in patients with multiple myeloma or if the investigators can arrest the progression of the patient's condition condition (described above) to multiple myeloma. These TAA-specific CTLs are an investigational product not approved by the Food and Drug Administration. The purpose of this study is to find the largest safe dose of TAA-specific CTLs, to learn what the side effects are, and to see whether this therapy might help patients with multiple myeloma monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM) .
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: